GRAIL, Inc. (GRAL) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. GRAIL, Inc. is a commercial-stage healthcare company focused on early cancer detection via its Galleri multi-cancer early detection (MCED) blood test. The company operates as a single reporting segment and is classified as an emerging growth company. Following a spin-off from Illumina, Inc. in June 2024, GRAIL continues to pursue FDA Pre-Market Approval (PMA) for Galleri, which was submitted in January 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $40.8 million | $31.8 million |
| Net Loss | $(93.2) million | $(106.2) million |
| Net Loss Per Share (Basic & Diluted) | $(2.29) | $(3.10) |
| Adjusted EBITDA | $(79.9) million | $(98.7) million |
| Cash & Cash Equivalents | $69.3 million | $133.9 million |
| Short-Term Marketable Securities | $753.8 million | $654.7 million |
| Total Liquidity (Cash + Securities) | $823.1 million | $788.6 million |
| Net Cash Used in Operating Activities | $(87.0) million | $(95.0) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 28% year-over-year to $40.8 million. Screening revenue rose 37% to $39.8 million, driven by a 50% increase in Galleri test volume, partially offset by a 9% decrease in average selling price (ASP). Conversely, development services revenue declined 65% to $0.95 million due to fewer biopharmaceutical pilot programs.
- Expense Reduction: Total operating expenses decreased 5% to $176.6 million. Research and Development (R&D) expenses fell 10% to $48.0 million, and Sales and Marketing expenses dropped 12% to $30.7 million, primarily due to reduced headcount and lower non-recurring marketing costs.
- Profitability: The net loss narrowed by $13.0 million compared to the prior year, improving from $(106.2) million to $(93.2) million. Adjusted Gross Profit improved to $19.7 million from $14.3 million, reflecting better fixed cost leverage.
- Liquidity: While cash and cash equivalents decreased significantly due to operating outflows, the company increased its holdings in short-term marketable securities by $99.1 million, resulting in a net increase in total liquidity.
Outlook, Risks, and Management Commentary
- Regulatory Status: GRAIL submitted its PMA application to the FDA in January 2026. Management expects FDA approval to be a critical catalyst for broader commercial reimbursement, particularly under a new law creating a Medicare coverage benefit category for FDA-approved MCED tests (potentially effective Jan 1, 2029).
- Clinical Trial Results: Top-line results from the NHS-Galleri trial were announced in February 2026. While the trial showed a substantial reduction in stage 4 diagnoses and increased early-stage detection, it did not meet the primary endpoint of a statistically significant reduction in combined stage 3 and 4 cancers. This announcement caused a material decrease in market capitalization, triggering an impairment review (which resulted in no write-down).
- Capital Resources: Management believes existing cash and marketable securities are sufficient to fund operations into 2030. However, the company anticipates needing additional financing in the future.
- Pending Investment: A $110 million private placement with Samsung Investors (Samsung Stock Purchase Agreement) signed in October 2025 remains pending, subject to regulatory approvals including CFIUS clearance.
- Royalty Suspension: Royalty payments to Illumina are suspended until December 24, 2026. Had royalties been payable in Q1 2026, the expense would have been $2.9 million.
- Legal Proceedings: The company is involved in consolidated securities class action litigation regarding the Illumina acquisition. The court recently granted a motion to dismiss with leave to amend; the plaintiffs filed a third amended complaint in October 2025, and GRAIL filed a motion to dismiss in December 2025.
Investor Verification Checklist
- Impairment Review: Verify the assumptions used in the recoverability test for long-lived assets following the market cap decline post-NHS-Galleri results.
- Samsung Investment Closing: Monitor the status of regulatory approvals (CFIUS) required to close the $110 million Samsung investment.
- Reimbursement Pathway: Track the FDA PMA review timeline and the specific criteria for the new Medicare MCED benefit category.
- Customer Concentration: Note that one customer accounted for 11% of revenue in Q1 2026, up from no single customer exceeding 10% in Q1 2025.
- Legal Exposure: Assess the potential financial impact of the ongoing securities class action litigation and any indemnification obligations.